Login to Your Account

CancerVax Tumbles On Poor Canvaxin Data, Cuts 100 Jobs

By Jennifer Boggs

Wednesday, October 5, 2005
Disappointing interim results from a Phase III trial of its lead cancer drug, Canvaxin, prompted CancerVax Corp. to stop development of the drug and downsize the company's work force by more than half. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription